404 related articles for article (PubMed ID: 29621758)
1. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
Xie J; Li Q; Ding X; Gao Y
Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
[TBL] [Abstract][Full Text] [Related]
2. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
Li X; Li Z; Song Y; Liu W; Liu Z
Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
[TBL] [Abstract][Full Text] [Related]
3. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
[TBL] [Abstract][Full Text] [Related]
4. Autophagy induction contributes to GDC-0349 resistance in head and neck squamous cell carcinoma (HNSCC) cells.
Zhou Y; Peng Y; Tang H; He X; Wang Z; Hu D; Zhou X
Biochem Biophys Res Commun; 2016 Aug; 477(2):174-80. PubMed ID: 27291151
[TBL] [Abstract][Full Text] [Related]
5. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.
Li Q; Song XM; Ji YY; Jiang H; Xu LG
Biochem Biophys Res Commun; 2013 Nov; 440(4):701-6. PubMed ID: 24103749
[TBL] [Abstract][Full Text] [Related]
6. Targeting mTOR by CZ415 Suppresses Cell Proliferation and Promotes Apoptosis via Lipin-1 in Cervical Cancer In Vitro and In Vivo.
Zhang J
Reprod Sci; 2021 Feb; 28(2):524-531. PubMed ID: 32944878
[TBL] [Abstract][Full Text] [Related]
7. CC-223 inhibits human head and neck squamous cell carcinoma cell growth.
Wang JY; Jin X; Zhang X; Li XF
Biochem Biophys Res Commun; 2018 Feb; 496(4):1191-1196. PubMed ID: 29402408
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Bcl-2 potentiates AZD-2014-induced anti-head and neck squamous cell carcinoma cell activity.
Li Y; Cui JT
Biochem Biophys Res Commun; 2016 Sep; 477(4):607-613. PubMed ID: 27343560
[TBL] [Abstract][Full Text] [Related]
9. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
10. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
[TBL] [Abstract][Full Text] [Related]
11. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
[TBL] [Abstract][Full Text] [Related]
12. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
[TBL] [Abstract][Full Text] [Related]
13. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
[TBL] [Abstract][Full Text] [Related]
14. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
[TBL] [Abstract][Full Text] [Related]
15. A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Radhakrishnan A; Nanjappa V; Raja R; Sathe G; Puttamallesh VN; Jain AP; Pinto SM; Balaji SA; Chavan S; Sahasrabuddhe NA; Mathur PP; Kumar MM; Prasad TS; Santosh V; Sukumar G; Califano JA; Rangarajan A; Sidransky D; Pandey A; Gowda H; Chatterjee A
Sci Rep; 2016 Oct; 6():36132. PubMed ID: 27796319
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.
Schedel F; Pries R; Thode B; Wollmann B; Wulff S; Jocham D; Wollenberg B; Kausch I
Oncol Rep; 2011 Mar; 25(3):763-8. PubMed ID: 21240463
[TBL] [Abstract][Full Text] [Related]
17. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
18. Bromodomain-Containing Protein 4 (BRD4) Inhibition Sensitizes Palomid 529-Induced Anti-Renal Cell Carcinoma Cell Activity in Vitro and in Vivo.
Xing ZY; Wang Y; Cheng L; Chen J; He XZ; Xing W
Cell Physiol Biochem; 2018; 50(2):640-653. PubMed ID: 30308518
[TBL] [Abstract][Full Text] [Related]
19. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
[TBL] [Abstract][Full Text] [Related]
20. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]